Recently, Hideshima et al. showed that perifosine, an alkylphospholipid, is active in-vitro against myelomatous cells by inhibiting the phosphatidilinositol 3-kinase/Akt, a mitogen-activated protein kinase which mediates MM cell resistance to conventional therapies [29]. This evidence concerns the gene AKT1 and Miyoshi myopathy.